908 Devices (NASDAQ:MASS) Announces Quarterly Earnings Results, Beats Estimates By $0.01 EPS

908 Devices (NASDAQ:MASS) posted its quarterly earnings results on Tuesday. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01, Zacks reports. 908 Devices had a negative net margin of 7.17% and a negative return on equity of 22.31%. The company had revenue of $17.38 million during the quarter, compared to analyst estimates of $16.19 million.

Here are the key takeaways from 908 Devices’ conference call:

• Q4 revenue from continuing operations was $17.4 million, up 21% year‑over‑year, driven by demand for XplorIR, initial VipIR shipments, and strong U.S. state & local adoption.
• The company achieved positive adjusted EBITDA of $0.7 million in Q4 (vs. a loss of $4.0M a year ago) after cost and manufacturing consolidation, and targets cutting the 2025 adjusted EBITDA loss roughly in half in 2026 to the mid‑single‑digit millions.
• Product momentum is accelerating — shipped more than 40 VipIR units in Q4 (~$3M revenue) and delivered over 150 quant‑enabled XplorIR units in 2025 (XplorIR +40% YoY); the next‑gen MX908 platform is planned for commercial launch in 2026.
• Financial position strengthened with $113 million in cash and no debt, giving flexibility to invest in growth and support programs like AVCAD, for which the company expects $2M–$3M of revenue in 2026.
• Despite quarterly improvement, full‑year 2025 reported a net loss from continuing operations of $33.3 million and an adjusted EBITDA loss of $9.6 million, driven largely by non‑cash goodwill impairment and contingent consideration valuation changes, indicating ongoing profitability risks.

908 Devices Price Performance

Shares of MASS stock traded up $0.41 during trading hours on Wednesday, reaching $6.73. 104,174 shares of the stock were exchanged, compared to its average volume of 326,113. The business’s fifty day moving average is $6.15 and its two-hundred day moving average is $6.64. The firm has a market capitalization of $243.56 million, a P/E ratio of -61.18 and a beta of 0.47. 908 Devices has a 12-month low of $2.67 and a 12-month high of $9.34.

Key Headlines Impacting 908 Devices

Here are the key news stories impacting 908 Devices this week:

• Positive Sentiment: Q4 results beat expectations — 908 Devices reported a loss of $0.05/share vs. Street -$0.06 and revenue of $17.38M vs. consensus $16.19M, showing sequential improvement in top-line execution. View Press Release
• Positive Sentiment: FY2026 revenue guidance slightly above consensus — management set revenue guidance of about $64.5M–$67.5M versus a consensus near $65.4M, which supports modest top-line growth expectations for the year. Article
• Neutral Sentiment: Conference materials and call transcripts are available for detailed read-through — management commentary and slide deck can clarify product pipeline and cadence of revenue. Listen to Conference Call View Slide Deck
• Neutral Sentiment: Short-interest reports flagged a “large increase” but the published figures are inconsistent (zeros/NaN) and appear unreliable — treat short-interest changes as noise until clarified by an official data source.
• Negative Sentiment: Company remains unprofitable and loss-making metrics persist — Q4 negative net margin (~-7.2%) and negative ROE (-22.3%); the company still expects FY results to be loss-making, which caps upside until sustained profitable growth is visible. Article
• Negative Sentiment: Management did not provide clear EPS guidance for FY2026 in the release (EPS guidance field left empty), which can increase near-term uncertainty for estimates and analyst modeling.

Insider Buying and Selling at 908 Devices

In other 908 Devices news, CFO Joseph H. Iv Griffith sold 23,175 shares of the company’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $6.18, for a total transaction of $143,221.50. Following the completion of the transaction, the chief financial officer owned 139,896 shares in the company, valued at approximately $864,557.28. This represents a 14.21% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 23.70% of the company’s stock.

Hedge Funds Weigh In On 908 Devices

Institutional investors and hedge funds have recently modified their holdings of the company. Millennium Management LLC grew its stake in 908 Devices by 409.0% in the 4th quarter. Millennium Management LLC now owns 158,103 shares of the company’s stock worth $830,000 after acquiring an additional 127,040 shares during the period. Engineers Gate Manager LP acquired a new position in 908 Devices during the fourth quarter worth approximately $140,000. Bridgeway Capital Management LLC raised its holdings in shares of 908 Devices by 65.6% in the 4th quarter. Bridgeway Capital Management LLC now owns 50,500 shares of the company’s stock worth $265,000 after purchasing an additional 20,000 shares during the period. First Light Asset Management LLC grew its stake in shares of 908 Devices by 92.6% in the fourth quarter. First Light Asset Management LLC now owns 4,836,186 shares of the company’s stock valued at $25,390,000 after buying an additional 2,325,690 shares in the last quarter. Finally, State of Wisconsin Investment Board bought a new stake in shares of 908 Devices in the 4th quarter worth about $170,000. Hedge funds and other institutional investors own 88.06% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of 908 Devices in a report on Wednesday, January 21st. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $12.00.

About 908 Devices

908 Devices Inc (NASDAQ: MASS) is a developer and manufacturer of portable analytical instruments designed to deliver rapid chemical detection in field and laboratory environments. The company’s core focus lies in miniaturizing high-performance mass spectrometry and ion mobility spectrometry technologies, enabling users to perform on-site analysis that traditionally required benchtop equipment.

Key products in 908 Devices’ portfolio include the MX908, a handheld high-resolution mass spectrometer capable of detecting and identifying a broad range of chemicals and explosives; the M908 portable mass spectrometer for laboratory or mobile units; and the ZipChip capillary electrophoresis system for high-throughput, microfluidic separations.